

THE PRODIGY STUDY AT A GLANCE.

GLOBAL STUDY OF RESPIRATORY COMPROMISE, A TOP PATIENT SAFETY ISSUE.



PRODIGY

Prediction of **O**pioid-induced
Respiratory **D**epression **I**n Patients
Monitored by Capno**G**raph**Y**

About respiratory compromise

In respiratory compromise, there is a high likelihood of decompensation into respiratory failure or death, but continuous monitoring and early intervention might prevent or mitigate decompensation.¹

The number of respiratory compromise cases is on the rise and can occur anywhere in the hospital.^{2,3}

Patients receiving opioids may be at increased risk of experiencing respiratory compromise.⁴

Respiratory compromise is common, costly, and deadly — but preventable:


- **Common** — a leading patient safety issue⁵
- **Costly** — top-five condition leading to increasing hospital costs; fifth-most rapidly increasing hospital inpatient cost in the United States⁶
- **Deadly** — general care floor patients with respiratory compromise are 14.4 times more likely to die⁷
- **Preventable** — in many cases, respiratory arrests are potentially avoidable⁸

About the PRODIGY study

PRODIGY, a global, Medtronic-sponsored, 16-site prospective study, is the largest of its kind and fills significant knowledge gaps in the prevention of opioid-induced respiratory depression (OIRD), a form of respiratory compromise.

Its primary objective was to develop an easy-to-use OIRD Risk Prediction Tool. This tool provides a PRODIGY Risk Score, which serves as a guide to identifying patients who would benefit most from continuous monitoring including capnography and oximetry on the general care floor.

The study found that:



46 percent of patients experienced respiratory depression episodes (RDEs).⁹



Patients experiencing RDEs show evidence of poorer outcomes.⁹

Patients with ≥ 1 respiratory depression episode were more likely to experience an adverse event that required action.⁹



Patients experiencing RDEs also show increased costs and increased lengths of stay (LOS).⁹ In patients with ≥ 1 RD episode, mean hospital length of stay was three days longer.⁹

Medtronic
Further, Together

The PRODIGY Risk Prediction Tool can help identify patients at increased risk — and guide the use of continuous monitoring, including capnography and oximetry.



PRODIGY RISK PREDICTION TOOL

| Risk Factors | Scoring Criteria | Points | Score |
|----------------------------------|-----------------------------------|----------|-------|
| Patient Age (years) | Age < 60 | = 0 pts | |
| | Age 60–69 | = 8 pts | |
| | Age 70–79 | = 12 pts | |
| | Age ≥ 80 | = 16 pts | |
| Sex | Male | = 8 pts | |
| | Female | = 0 pts | |
| Previous Opioid Use | Opioid naïve | = 3 pts | |
| | Previous opioid use | = 0 pts | |
| Sleep Disordered Breathing (SDB) | Known SDB or high STOP-BANG score | = 5 pts | |
| | No SDB or normal STOP-BANG score | = 0 pts | |
| Chronic Heart Failure (CHF) | Coexisting CHF | = 7 pts | |
| | No known CHF | = 0 pts | |
| Total PRODIGY Risk Score | | | |

PRODIGY Risk Level

- ☐ Low risk of respiratory depression episodes for less than 8 pts
- ☐ Intermediate risk of respiratory depression episodes for 8–14 pts
- ☐ High risk of respiratory depression episodes for 15 pts or higher

1. Morris TA, Gay PC, MacIntyre NR, et al. Respiratory compromise as a new paradigm for the care of vulnerable hospitalized patients. *Respir Care*. 2017 Apr;62(4):497–512. 2. Agarwal SJ, Erlson MG, Bloom JD. Projected incidence and cost of respiratory failure, insufficiency and arrest in Medicare population, 2019. Abstract presented at AcademyHealth Congress, June 2011. 3. Wang HE, Abella BS, Callaway CW. Risk of cardiopulmonary arrest after acute respiratory compromise in hospitalized patients. *Resuscitation*. 2008;79(2):234–240. 4. Dahan A, Aarts L, Smith TW. Incidence, reversal, and prevention of opioid-induced respiratory depression. *Anesthesiology*. 2010;112:226–238. 5. ECRI Institute. Executive Brief. Top 10 patient safety concerns for healthcare organizations. 2016. <https://www.ecri.org/components/HRC/Pages/Top10Survey.aspx>. Accessed Feb 1, 2019. 6. Wier LM (Thomson Reuters), Henke R (Thomson Reuters), Friedman B (AHRQ). Diagnostic groups with rapidly increasing costs, by payer, 2001–2007. HCUP Statistical Brief #91. June 2010. Agency for Healthcare Research and Quality, Rockville, MD. <http://www.hcup-us.ahrq.gov/reports/statbriefs/sb91.pdf>. Accessed Feb 1, 2019. 7. Buist M, Bernard S, Nguyen TV, Moore G, Anderson J. Association between clinically abnormal observations and subsequent in-hospital mortality: a prospective study. *Resuscitation*. 2004;62(2):137–141. 8. Lee LA, Caplan RA, Stephens LS, et al. Postoperative opioid-induced respiratory depression: a closed claims analysis. *Anesthesiology*. 2015;122(3):659–665. 9. Khanna A, Bergese S, Jungquist CR, Morimatsu H, Uezono S, Lee S. Prediction of opioid-induced respiratory depression on inpatient wards using continuous capnography and oximetry: an international prospective, observational trial. *Anesth Analg*. 2020; in press.

© 2020 Medtronic. All rights reserved. Medtronic, Medtronic logo and Further, Together are trademarks of Medtronic. All other brands are trademarks of a Medtronic company. 03/2020–17-PM-0126(1)a-[WF#3988712]

6135 Gunbarrel Avenue
Boulder, CO 80301

800.635.5267

[medtronic.com/covidien](https://www.medtronic.com/covidien)

Medtronic